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Dear Reader,
I first started working with Osmosis as a Sophomore 
when Alex Long was preparing to gather together its 
second issue. He heard through the grape vine that I 
knew how to use Adobe InDesign. At first, I saw Osmosis 
as purely a healthcare magazine, and as a non-pre-med, 
just-pre-graduate-school student— I thought it wasn’t 
for me. Through my ~3 years with Osmosis, I have come 
to the conclusion that Osmosis is NOT just a healthcare 
magazine, and contrary to our title, it is NOT just a science 
magazine. Osmosis is for everyone. Osmosis is for the pre-
law, the environmentalist, the faculty, and the conscious 
citizen. I am so grateful that I have been able to watch 
Osmosis grow through my time at UR, and I’m even more 
grateful that some loyal Osmosis writers have been here 
since the beginning. Adriana Grimes is a graduating senior 
that has been writing since the first issue! I hope that in the 
future we are able to gather even more loyal team members 
and continue to grow in the right direction. I know from personal experience that Osmosis has helped me grow 
in the right direction. Throughout my short scientific career, Osmosis has reminded me of the importance of 
communicating science to a wider audience. As I prepare to graduate and  go off to graduate school, I know I 
would not have had nearly the same undergraduate experience if it was not for Osmosis. Good luck to next year’s 
editor, Anthony Isenhour, I know I’m leaving Osmosis in good hands :)
 Your editor, 
Mickey Murvin
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ore than 50 percent of adults over the age of 18 
drink coffee every day.1 Students on our own cam-
pus are not unfamiliar with the idea of a cup of coffee, 
or more, a day. But, could there be an alternative to this 
morning routine? Do we have to run on Dunkin? Kent 
Chen and Ryan Yoshimura worked with surgeons from 
UCLA to develop an exciting new energizer that would 
provide better results than the energizers used in the 
past. In 2015, they introduced Neurogum to the mar-
ket.2 Its purpose is to boost energy, cognition, and focus 
whether it is to study for a test or run a mile.
 Neurogum contains natural caffeine, L-the-
anine, and B-vitamins that were combined to give a 
longer attention boost than regular caffeine. Forty 
milligrams of caffeine was incorporated into the gum to 
reduce the risk of Alzheimer’s disease, as well as demen-
tia. Several studies examining the relationship between 
caffeine and dementia have agreed that caffeine does 
play a role in protecting against the onset of Alzheimer’s 
disease and dementia-related diseases. A linear study re-
viewing other studies, illustrated that the results, overall, 
presented agreements under various conditions.3  
 L-theanine is an amino acid contained in teas, 
such as green and black tea, and is said to be a com-
plement to caffeine. It is suggested that L-theanine can 
enhance the user’s focus, while also decreasing the neg-
ative effects of coffee, such as restlessness and stomach 
discomfort, and stress.4 Sixty milligrams of L-theanine 
is added, which is a greater than the amount of caffeine 
in Neurogum. The L-theanine directly affects brain waves, 
called alpha waves, which reduces stress without the som-
nolent effects of relaxation.5 Usually, this ideal reaction 
from L-theanine is not found within a normal cup of tea, 
which contains only about 20 milligrams of the substance. 
The 60 milligrams of L-theanine added is equivalent to 
three cups of tea in one dense, small piece of gum. 
 The last of the ingredients include vitamins B6 
and B12. Vitamin B6 assists with the production of neu-
rotransmitters6; while, B12 helps produce DNA.7 These 
vitamins have many other functions as well, but they are 
also added in combination with the caffeine and L-the-
anine to promote the effects of all ingredients. This com-
bination of ingredients allows the gum to extend cognitive 
function within the body of its consumer. 
 Theoretically, almost every aspect of this gum and 
its production plays a role in creating the desired effects 
for consumers. For example, this gum is made using a 
cold compress rather than applied heat, which allows it to 
maintain all of its ingredients upon utilization.8 The cre-
ators also emphasize that the route of administration for 
this product maximizes its ingredients, as well. Absorp-
tion via the oral mucosa is heavily understood to be faster 
and more efficient than digestion, which supports the idea 
of a gum rather than a drink.8 The thoroughness of their 
research further extends the value of this product. They 
prove its value appreciably in their written work, as they 
justify other decisions when manufacturing this gum that 
help maximize the ingredients. This product is a seeming-
ly easy-to-use replacement for coffee, and with zero grams 
of sugar, Neurogum may be worthwhile for busy students 
seeking healthier lifestyles.
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veryone loves eating too many carbs and realistically 
the occasional food-binge doesn’t harm the body 
very much. For some people, however, it can. For peo-
ple in the United States who have been diagnosed with 
Auto-brewery Syndrome, or Gut Fermentation Syndrome, 
carbo-loading (eating copious amounts of carb-heavy 
food at once) can have some legal and behavioral conse-
quences.
 Auto-brewery Syndrome is a condition where the 
yeast within your gut produce ethanol through fermenta-
tion instead of traditional aerobic respiration. For people 
with this condition who eat large amounts of carbs in 
one meal, they end up with low levels of alcohol intoxica-
tion.1 Scientists have known about this 
phenomenon for about a century, de-
scribing it as “abnormal gut syndrome,” 
“germ carbohydrate fermentation,” and 
“intestinal carbohydrate dyspepsia” as 
far back as 1912.2 
 This syndrome has been shown 
to affect adults and children and could 
be a possible cause for sudden infant 
death. People with this condition can 
also experience side effects such as 
hangovers, belching, disorientation, 
and chronic fatigue.1 Having a gut that 
can make its own alcohol seems fun, 
but controlling it isn’t as easy as you 
might think.
 Auto-brewery Syndrome 
happens because the yeast within the 
gut go through anaerobic respiration, 
also known as fermentation. This 
means that when breaking down the 
sugars from the carbs you eat, they produce ethanol as a 
byproduct. Your liver typically metabolizes and breaks 
down alcohol, but this extra production by yeast leads to 
an increased alcohol content in your body even leading 
to getting drunk. In treating this unintentional alcohol 
intake, doctors typically recommend low carbohydrate 
diets, as well as probiotic supplements to increase the 
amount of normal bacteria in your gut.1
 Because individuals with this syndrome do not 
always know when it happens, multiple people have at-
tempted to use this syndrome as a drunk-driving defense 
in court. In 2015, a woman from upstate New York was 
charged with a DWI (driving while intoxicated) hours 
after having had her last drink. When pulled over while 
driving with a flat tire, her blood alcohol content (BAC) 
was 4 times over the legal limit. She was taken to the 
hospital, as standard protocol for this BAC level, but was 
released because she presented no symptoms. In fur-
ther testing she was found to have an increased alcohol 
tolerance that correlates to the level of functioning 
alcoholics. Her charges were dismissed by a judge after 
presentation of her possessing this syndrome.3
 In early March of 2019, however, a man from 
Maine attempted to use this syndrome as a defense for 
his own DWI. His appeal was denied, but not strictly in 
response to whether or not he had this syndrome. The 
judge felt that the possibility of using an “ignorance” 
approach as a legal loophole to drunk driving made the 
ruling a particularly important one. The judge made 
clear his dismissal of the appeal was not on the grounds 
of the man having this syndrome or not, but 
that his witnesses attesting to this appeal 
were untrained or not provided in a 
timely manner.4 This syndrome does 
raise the question: Can individuals 
with Auto-brewery Syndrome 
be convicted for driving while 
intoxicated if they have BACs 
that are unintentionally over the 
legal limit?
 While being able to get drunk 
after eating too many carbs may 
seem fun, individuals with this 
syndrome struggle with the 
fluctuating levels of intoxica-
tion they experience. Addition-
ally, they may face unintentional 
conflicts with the law, as well as the 
detrimental effects of continuous alcohol 
within their bodies. 
E
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one of the most popular fetishes.5 
The second theory is “early childhood imprinting”, which 
states that early childhood experiences are reflected in 
the fetishes present in adulthood. Within this, there are 
two proposed theories: the conditioning and the trauma 
theory.  The conditioning model theorizes that fetishes 
develop when a stimulus is paired with sexual thoughts 
or behavior.3 Studies have shown that men can be con-
ditioned to have erections from traditionally non-sexual 
stimuli (i.e. types of clothing) if they were first paired 
with sexually explicit photographs.7 Researchers paired 
sexually explicit photos with a pair of women’s boots and 
colored geometric figures and found that some men could 
develop erections in response to the non-sexual stimu-
li alone. These results, however, should be taken with a 
grain of salt due to small sample sizes and lack of control 
conditions.7 The trauma model is based on the idea that 
fetishes are rooted in either emotionally or physically 
traumatic experiences in childhood or adolescence.3 This 
also includes unresolved emotions from childhood or 
growing up in sexually restrictive households.3 Howev-
er, most experts agree that the conditioning and trauma 
models do not fully account for the development of 
fetishes because not everyone develops fetishes and some 
stimuli are fetishized more easily. 
 There are a lot of reasons why sexual fetishes 
could develop and in whom they develop. There are in-
teresting patterns that are present in preliminary studies, 
but more in-depth research is needed before any concrete 
statements can be made about fetishes and sexual fanta-
sies.
fetish is defined by the Oxford Dictionary as 
“a form of sexual desire in which gratification 
is linked to an abnormal degree to a particular object, 
item of clothing, part of the body, etc.”1 The diagnostic 
statistical manual (DSM), which defines psychological 
disorders,2 has also defined fetishes. Fetishes, however, 
are not defined as a disorder unless they confer a serious 
or significant detriment or distress for the person.3 Most 
individuals who self-describe as having fetishes or being 
fetishists do not fall into the category of having 
clinical impairments due to the fetish.2 
So how do sexual fantasies differ 
from fetishes? Sexual fantasies are 
broader than fetishes and include 
sexual desire for certain behaviors 
but may also include fetishes. This 
article aims to examine fetishes as 
defined by the Oxford Dictionary 
in which the person is not clini-
cally impaired. In other words, this 
article will explore fetishes between 
consenting adults for the sexual enjoyment of all parties 
involved.
 So how common are fetishes and “deviant” sex-
ual fantasies? Unsurprisingly, this is an under studied 
field. Thus, the data has come from a variety of places. 
The two main sources are the internet and clinical case 
studies (when someone sees a therapist). Canadian 
researchers conducted a study of around 1,500 adults to 
see which sexual fantasies are common and which are 
rarer.4 Of the 55 sexual fantasies studied, only two fan-
tasies were found to be rare, and nine were found to be 
unusual for men and women.4 Thirty fantasies were de-
scribed as common for one or both genders; while, only 
five were found to be typical.4 The researchers caution 
against taking these results too seriously, as the sex sur-
veys are likely to attract people who are more comfortable 
in their sexuality and sexual behaviors than those who are 
not.4 One interesting find between men and women was 
that women are more likely to have a submissive fantasy 
(30-60 percent of those surveyed), and men are more 
likely to have a dominant fantasy (40-60 percent).4 As in, 
women are more likely to want to be spanked, tied up, 
whipped, and overall dominated; whereas, men are more 
likely to want to perform dominating behaviors. However, 
a significant portion of men also have sexual submission 
fantasies and women also have sexual dominant fanta-
sies.4 It is clear that many of what individuals outwardly 
consider to be deviant sexual fantasies are not, in fact, as 
abnormal as they appear. A cursory internet search per-
formed by anyone with Wi-Fi will only drive that point 
home.
  Of fetishes, which are the most common? 
A survey of nearly 400 discussion groups, which looked 
at approximately 5,000 individuals, calculated the prev-
alence of different fetishes.5 They found that fetishes for 
body parts and objects related to the body were the most 
common at 33 and 30 percent, respectively.5 Preferences 
for other people’s behavior comprised 18 percent; while, 
a person’s own behavior and social behavior each made 
up 7 percent.5 Objects unrelated to the body made up 
just 5 percent.5 Within the category of 
body parts, the most frequent by a large 
margin is feet podophilia, at 47 percent 
relative frequency.5 This is followed by 
body fluids (urine, feces, blood, etc.) at 9 
percent and body size (tall, short, weight, 
etc.) also at 9 percent.5 With regards to 
objects associated with the body, the most 
common are objects worn on the legs and but-
tocks at 33 percent, followed closely by footwear at 
32 percent.5 The next largest category is underwear at 
12 percent.5
 Why and how do humans develop fetishes? There 
are two main theories to explain why and how humans 
develop fetishes. One of the most popular is the “signals 
crossing” theory, which helps explain the etiology of foot 
fetishes.6 In the human brain, the senses are mapped; spe-
cific locations in your brain correlate to specific locations 
on the body.6 The part of the brain that is triggered when 
the genitals are stimulated is adjacent to the part of the 
brain that is mapped to the feet.6 It is theorized that some 
people have an overlap in neurons of these areas.6 Basi-
cally, the boundaries of the map overlap, meaning that 
feet can cause sexual arousal in a person.6 This includes 
looking at, touching, and smelling feet, either their own 
or another individual’s. This is what is defined as a foot 
fetish. This also may be the reason that foot fetishes are 
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ancer is a deadly disease affecting and 
killing many people every year. For 2019, 
the estimated number of new cancer cases 
exceeds 1.5 million, and the estimated number 
of deaths caused by cancer exceeds six-hundred 
thousand.1 Treatments for cancer certainly exist; 
although current treatments are often costly and are 
not always effective in the long-run. The treatments 
also come with side effects often associated with 
the destruction of healthy, noncancerous cells. 
The expansion of alternatives for treating cancer 
is a constant objective for the medical community, 
and researchers are experimenting with many new 
solutions in order to provide new opportunities to treat 
cancer. One potential treatment in development is 
snake venom, a substance that is normally poisonous 
to humans in its unmodified form.
 Although snake venom as a whole can be 
harmful to humans, it is composed of many different 
proteins, enzymes, and carbohydrates. If the different 
molecules constituting the venom are extracted and 
isolated, the individual molecules can provide benefits 
for humans without the harmful effects of the entire 
venom. For example, the drug captopril is derived 
from snake venom and treats high blood pressure and 
heart failure. As long as the entire venom is not used, 
the separate components can elicit healthy effects in 
humans. In the 1940s, researchers began isolating 
enzymes and non-enzyme proteins from snake venom 
and experimented with the proteins for effects on 
tumor cells. Clinical testing with the venom became 
more prevalent from the 1960s onward.2, 3
 The proteins in snake venom harbor a variety 
of cancer-
fighting characteristics. 
One such type of protein is the disintegrin. 
Disintegrins are non-enzymatic proteins found 
in snake venom and inhibit angiogenesis, the 
development of new blood vessels. Angiogenesis 
allows tumor cells to invade nearby healthy tissue and 
metastasize. Treatment with disintegrins has been 
shown to suppress the spread of tumors due to the 
antiangiogensis activity of disintegrins.3 
L-amino acid oxidases (LAAOs) are enzymatic 
proteins found in snake venom and demonstrate 
anti-tumor effects. LAAO converts L-amino acid to 
alpha-keto acid and releases the byproducts ammonia 
and hydrogen peroxide. Hydrogen peroxide is a major 
proposed mechanism of LAAO-induced toxicity, as it 
can act as reactive oxygen species (ROS) that can 
diffuse into cancer cells and cause cell death. Studies 
have shown that the effects of ROS are more likely to 
harm cancer cells than normal cells, possibly due to 
the higher metabolic activity present in cancer cells. 
The higher metabolic activity leads to higher levels 
of ROS in cancer cells; hence, the cancer cells are 
more susceptible to further increases in ROS levels 
than normal cells. The evidence of selectivity of LAAO 
activity towards cancer cells is beneficial for cancer 
therapy, as the enzyme does not seem to have a high 
potential to harm healthy cells.4
Metalloproteases (MPs) are another group of enzymes 
derived from the venom and can also exhibit anti-
tumor activity.5 One type of MP, known as jarahagin 
(produced by the species Bothrops jararaca), has 
demonstrated cytotoxic effects on melanoma cells, 
as well as inhibition of cancer cell adhesion.6 Cell 
adhesion contributes to tumor spread; thus, by 
inhibiting adhesion, jarahagin can prevent metastasis, 
which is the spread of cancer to a secondary site. 
Phospholipase A2 (PLA2) is another enzyme 
belonging 
to snake 
venom and has 
demonstrated cytotoxic and 
antiangiogenesis effects.5
 Lectins (proteins that bind to sugars) belonging 
to snake venom have been shown to inhibit the 
growth of certain types of cancer cells, such as renal 
and pancreatic cancer cells.5 The proteins have 
also demonstrated cytotoxic activity. In a particular 
experiment, the lectin B1L, belonging to Bothrops 
leucurus venom, was tested and induced apoptosis on 
a variety of cancer cells, including myeloid leukemia 
cells, lung carcinoma, and larynx carcinoma cells. 
Furthermore, healthy cells were not harmed by the 
protein.7 Thus, snake venom lectins can be especially 
helpful in treating certain types of cancer. 
 The process of collecting the venom and 
determining its effects on cancer takes multiple 
steps. The species of snake from which the venom 
is collected depends on the proteins of interest, as 
the type of venom varies among species. It may be 
easier to collect venom in the summer as opposed 
to the winter, as the venom is more liquefied in the 
summer.8 Once the species is identified and captured, 
the snake must be kept in conditions suitable for living. 
A snake can die when kept in conditions unlike its 
natural habitat, and high occurrences of snake deaths 
could shift a vulnerable species closer to becoming 
endangered.2 Once the venom is collected, the 
proteins must be isolated using various purification 
techniques, such as size-exclusion, ion exchange, and 
affinity chromatography. Edman sequencing can be 
used to determine the sequences of small proteins, if 
necessary.9 Once the individual proteins of the venom 
are identified and isolated, researchers can test the 
effects of the proteins on cancer cell activity. 
 The isolation and utilization of snake venom 
components is a valuable cancer-fighting technique 
but is not without its flaws. The immune system can 
possibly react to foreign proteins injected into the 
bloodstream. Immunosuppression may help prevent 
rejection of the proteins by the immune system, but 
would also render the body vulnerable to infectious 
agents. Encapsulation of the proteins in nanocarriers 
for slow, controlled release of the proteins may help 
prevent adverse reactions by the immune system. 
The technique of encapsulation, however, has not 
fully been mastered and is currently in development.3, 
10 Furthermore, the mechanisms of action of many 
cancer-fighting proteins have not yet been confirmed, 
which is why many of these proteins are not yet 
available for purchase from pharmacies.11 Until the 
exact behavior of the snake venom components 
are made certain, there is no guarantee that these 
proteins cannot destroy healthy, noncancerous cells. 
Although many of the proteins have demonstrated 
selectivity towards tumor cells in experiments, further 
research should be done to confirm the abilities of 
these molecules to discriminate between cancerous 
and healthy cells and to determine potential methods 
to circumvent any possibility of the proteins harming 
healthy cells. 
 Snake venom as a treatment for cancer is 
promising and could be an effective alternative to 
current treatments. Whether or not the use of snake 
venoms would be more cost effective or less painful 
than current treatments has not yet been confirmed, 
as the treatment is not a common practice. Further 
research on the behavior of these proteins and on 
potential costs of treating cancer patients with the 
venom should provide more insight about the value of 
the treatment. In the future, when more information is 
made available, snake venom could potentially serve 
as an incredibly valuable alternative to current cancer 
treatments. 
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Why Do We Need the Flu Shot Every Year?
There is a need for a new vaccine every year due to 
antigenic drift. The antibodies that your body produced 
in response to last year’s flu shot are specific to the viral 
antigens from that year’s version of the vaccine. When 
a mutated version of that virus enters the body, these 
antibodies are no longer able to evoke an immune re-
sponse (Potter, 2008). Since the virus mutates slightly 
each season, new vaccines with slightly different an-
tigen combinations must be developed to recognize 
the hemagglutinin and neuraminidase proteins of the 
mutated virus.  Once the vaccine is administered, your 
innate immune system will create a cascade effect to 
activate B-cells to produce antibodies. If you were to 
contract the influenza virus, ideally your body would al-
ready have the necessary antibodies to fight the virus 
and produce minimal flu-like symptoms. The vaccine 
enables our bodies to combat the virus by generating 
antibodies in advance. Within two weeks of vaccination, 
the adaptive immune system should have generated 
appropriate defenses against contracting the seasonal 
strain of the flu (CDC). 
How Do I Choose a Vaccine?
The two most conventional types of flu vaccinations are 
egg based. These include the killed vaccine, taken as 
an intramuscular shot or live attenuated nasal spray 
vaccine (CDC). The killed vaccine involves injecting 
a fertilized hen egg with the influenza virus and later 
harvesting and purifying the viral fluid to acquire the in-
activated viral antigen. The live attenuated vaccination 
is a weakened version of four common strains of live 
influenza viruses. This attenuated nasal spray is not 
recommended for people over 50 or immunodeficient 
recipients. Live attenuated vaccine is cold adapted, so 
the virus cannot survive and replicate in the warm envi-
ronment of the lungs and cause an infection. Although 
vaccines are developed using viruses, the flu shot can-
not cause the flu.
Innovations within the past five years include cell-based 
and recombinant technology (Nation Vaccine Informa-
tion Center). The inactivated cell-based flu shot is pro-
duced in a similar way to the egg-based killed vaccine, 
but the viral antigen is extracted from a mammalian cell 
culture rather than utilizing chicken eggs. The recombi-
nant vaccine requires isolating a gene expressing viral 
specific protein. Typically the gene encoding for HA is 
injected into an insect virus, so it can be replicated with-
in insect cells. This process is faster than other meth-
ods because the virus does not need to undergo an at-
tenuation phase to grow in eggs or cell cultures (CDC). 
Recent Trials for Vaccine Development
Since the first influenza outbreak 100 years ago, a uni-
versal flu vaccine may become available in the near fu-
ture. BiondVax’s M-001 peptide vaccine has reached a 
phase 3 clinical trial in Europe. Instead of targeting the 
seasonally variable antigen surface of hemagglutinin 
and neuraminidase proteins, M-001 targets nine high-
ly conserved epitopes of the flu virus. These epitopes, 
which are part of an antigen that are recognized by the 
immune system, don’t change seasonally. So, ideally, 
you would only need one universal flu shot that would 
be effective for your lifetime. This approach allows for 
protection against all strains of influenza virus. Getting 
the universal vaccine in conjunction with the seasonal 
vaccine stimulates antibody production against hem-
agglutinin and has the most promising immunological 
success rate according to data acquired so far from the 
clinical trials (Taylor, 2018). About a dozen more influ-
enza universal vaccines, each founded upon slightly 
modified approaches, are in the earlier stages of clin-
ical trials. Increased public cooperation coupled with 
advancements in biomedical vaccination technology 
will hopefully lead to the stark decrease and eventual 
eradication of influenza viruses. 
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To this day, smallpox is the only disease confirmed to be 
eradicated worldwide. This would not have been possi-
ble without the first widely utilized vaccine developed 
nearly 200 years prior by Edward Jenner. Inspired by 
Jenner’s methodology of using the cowpox virus to pro-
tect against smallpox in humans, vaccine innovations 
and their significance to public health took off after Lou-
is Pasteur’s discovery of the rabies vaccine in 1885. 
Vaccines are perhaps the greatest immunological feat 
to this day. So why are people still so averse to getting 
vaccinated, especially for the flu? Encouraging people 
to get their annual flu shot and persuading the public of 
its effectiveness are two vital measures for preventing 
flu-related hospitalizations and deaths.
Flu History 
World War I played a significant role in the first influ-
enza outbreak. The war brought the mass mobilization 
of over 60 million soldiers with significantly different 
backgrounds and immune systems to highly concen-
trated war zones in Europe. This, coupled with years 
of unsanitary lifestyles, facilitated high transmission 
rates leading to the H1N1 influenza pandemic outbreak 
in 1918 (Matthews, 2014). Over 50 million people died 
and many more were infected by the end of this pan-
demic. At the time, the only preventative measure that 
was exercised was quarantine. 
About twenty years later, the influenza A and B viruses 
were isolated in the lab. Although vaccinations against 
this virus have been in development since the 1930’s, 
numerous clinical trials have debunked the effective-
ness of the influenza vaccine for decades after the 
1918 pandemic (National Vaccine Information Center). 
A century after the first influenza outbreak, the CDC re-
ported that the flu vaccine decreases the prevalence of 
flu related illness, hospitalization, and death, especially 
in young children and elderly people. Numerous stud-
ies have suggested that the trivalent influenza vaccine 
significantly reduces flu-related hospitalizations and fa-
talities (Nichols, 2018). The effectiveness of the flu vac-
cine varies from year to year depending on how well the 
projected vaccine antigen sequences matches the ac-
tual seasonal viral antigen. Although some years have 
better predictions than others, the overall effectiveness 
of the vaccine tends to be 40-60% (CDC). 
What is the Flu Virus?
The influenza virus is characterized by two envelope 
proteins. Hemagglutinin (HA) is the protein that allows 
the virus to attach to host cells, while neuraminidases 
(NA) release the virus from the host cell (Morgridge). 
There are sixteen known types of hemagglutinin and 
nine known types of neuraminidase, which gives 144 
different possible combinations of these proteins (Mor-
gridge). Different viral strains contain distinct hemag-
glutinin and neuraminidase proteins, such as H1N1, 
the most common influenza A known as the “swine flu.” 
Influenza vaccines contain three to four of the most 
common influenza strains, which are typically H1N1, 
H2N2, H2N3, and influenza B. The flu vaccine tends to 
be twice as effective in preventing H1N1 than H2N3 and 
influenza B (Rondy et al., 2018). This is one reason why 
the vaccine is not effective for everyone.
Waves of first influenza outbreak 1918 (Potter, 2008)
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interview, there have been assumptions that destitute popula-
tions and minority populations do not need genomic testing 
because infectious illnesses are a more prevalent and pressing 
concern than genetic diseases in such populations. However, 
over the years it has been proven that genetic diseases, such as 
heart disease and other chronic diseases, are also a significant 
concern in poor populations and minority populations just as 
in affluent or majority populations (Mullin 2016). 
Moreover, the genomes of many minorities and indigenous 
populations are more difficult to decode because of the nu-
merous diverse communities within each minority and indig-
enous population. This complexity appears to deter research-
ers because of the assumptions that the complexity will not 
provide accurate data to produce treatments (Santos 2008). 
For those few who do take on the challenge, the difficulty 
comes with great reward in discovering mutations and vari-
ants that often prove useful for medicine (Santos 2008). The 
unique qualities of minority and indigenous genomes provide 
greater knowledge on how genetics influence drug interac-
tions during treatment and other health issues like diabetes 
(Popejoy 2016). Therefore, concerning medical care, minority 
patients require just as much genetic data as the European 
patients, if not more because of the great diversity within the 
genomes of minority and indigenous populations that can 
provide great benefit to treatment and drug development. 
While ethics and assumptions show how the research com-
munity has been wrong in its execution of genetic studies, 
some aspects of the logistics of GWAS can hinder the abili-
ty to achieve diversity in studies. The primary logistical issue 
connects to historical points already mentioned. If people 
do not wish to contribute their genetic information due to 
historical oppression, discrimination, and unethical practice 
under false assumptions, then it proves extremely difficult to 
gather data on such populations today. The inability to attain 
samples from minorities slows progress towards diversifying 
the GWAS Catalog and other genetic databases, despite ef-
forts by programs like All Of Us, which was created by the 
NIH in 2018 to develop a database of at least a million diverse 
patient genomes (Yeager 2019). 
Due to how long the databases have been filled with Europe-
an majority, another logistical issue stems from the analyti-
cal models used to process the data produced by these mas-
sive GWAS. Analytical methods called ancestry metrics are 
used to process genomic data found in GWAS databases, but 
these metrics do not properly analyze an individual of a di-
verse background (Bustamante 2011). As a result, our current 
methodology of analysis likely produces a significant amount 
of error for genomes that carry more variants and deviate 
from the more homogenous populations that the metrics are 
based upon (Bustamante 2011). 
 The history of genetics research is riddled with ethical 
and logistical issues that have contributed to the present lack 
of diversity in GWAS. Incidents such as sampling bias based 
on supposed “race” and violation of minority patients’ con-
sent rights have caused logical issues for present day GWAS 
that seek to gather diverse genomes but cannot due to a lack 
of trust in research. Thankfully, several programs, similar to 
All Of Us, have been commissioned in recent years to create a 
better relationship between the public and researchers. While 
the past cannot be changed, the way in which future GWAS 
are constructed and conducted can be adjusted to achieve a 
genetic database that properly represents and provides Preci-
sion Medicine for the entire human species. 
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Precision medicine is a movement that seeks to serve a pa-
tient’s individual medical needs with a tailored level of treat-
ment. Such a practice requires an essential framework of 
genetic information to allow doctors to make accurate treat-
ment decisions. Genome-wide association studies (GWAS) 
provide massive amounts of information for databases, such 
as the GWAS Catalog; however, there is an apparent lack of 
diversity in the genomics data available to researchers and 
drug-developers. The majority of participants in GWAS are 
of European descent. As of January 2019, 78 percent of ge-
netics contributed by GWAS have been of European descent; 
while, only 22 percent are minorities (Yeager 2019). Stem-
ming from a history of discrimination and unfair logistics, 
the lack of diversity in genomic databases undercuts the ac-
cessibility and function of Precision Medicine, and this issue 
needs to be resolved.
After the completion of the human genome project in 2003, 
the ability to conduct GWAS and create a database of genetic 
information became possible and affordable. Over the past 
two decades, the data on human genetics has grown. Based 
on this growth, one would assume our knowledge of treat-
ments based on the unique genetic makeup patients would 
be vast and precise by now. At times, however, the procla-
mations of Precision Medicine overlook the history of ge-
netics— the percentage of European genetics in the GWAS 
Catalog remains the majority, even if they are not the ma-
jority by global population (Popejoy 2016). To understand 
how the lack of diversity in genetic databases developed, 
one must look at the questionable ethical history, medical 
assumptions, and objective logistics of genetic studies. 
Genetic research has had its share of ethically turbulent mo-
ments. As discussed by journalist Chou, the conversation be-
tween the scientific community and the public often struggles 
to distinguish between race and ethnicity of participants in 
genome studies (Chou 2017). The social construction of race 
is false, based on external phenotypes like skin color, and not 
backed by science because significant genetic variation ex-
ists even within the historical “five races”—African, Asian, 
European, Native American, and Oceanian— that have been 
used as a standard of categorization (Chou 2017). The genetic 
isolation of populations within the human species results in 
countless variations in phenotype and contributes to general 
ethnic differences and tendencies, which can greatly impact a 
patient’s health and lifestyle from a medical perspective. Thus, 
using ethnicity to minimize variables when categorizing data 
experimentally can be useful, but the variation within ethnic-
ity remains and makes constructing GWAS difficult (Chou 
2017). 
Another ethical factor, besides the issue of distinguishing 
race from ethnicity when gathering patient samples, is the 
blatant harm genetics research has inflicted on uninformed 
populations. One of the most striking examples concerns the 
Havasupai tribe in Arizona (Santos 2008). The Havasupai 
tribe agreed to a genetic study proposed by Arizona State 
University in the 1990s and were under the impression that 
the researchers would report the results and provide insight 
into the high frequency of type-2 diabetes in the tribe (Santos 
2008). However, the Havasupai never received a report from 
the study; in fact, the cell lines produced from the tribe’s sam-
ples were distributed among other universities, where studies 
deviating from the original agreement were conducted with-
out the Havasupai’s consent (Santos 2008). Consequently, the 
Havasupai filed lawsuits on the grounds of “exploitation and 
violation of civil rights” (Santos 2008). Numerous incidents 
similar to this have historically occurred in minority popu-
lations; a well-known example being the exploitation of cells 
from Henrietta Lacks, also known as HeLa cells. With such 
an unethical history of interaction with research endeavors, 
minorities commonly refuse to participate in genetic research 
studies, which contributes to the lack of diversity in GWAS 
(Santos 2008). 
Along with ethical issues, genetics research has also been 
conducted with certain assumptions in mind that simply do 
not hold true. As Adebowale Adeyemo, deputy director of the 
Center for Research on Genomics and Global Health at the 
National Human Genome Research Institute, highlights in an 
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n March 4, 1974, a nine-year-old boy was raped 
in his home in Lake Wales, Florida. When the 
police arrived, the boy described his assailant as possibly 
17 or 18 years old with a mustache and thick sideburns 
and named “Jim” or “Jimmy.” After being identified in a 
photograph lineup by the victim, Jimmy Bain, who said 
that he was at home watching television with his sister, 
was arrested and charged with child sex abuse, kidnap-
ping, and burglary/unlawful entry. During the trial, the 
prosecutors relied on both the photograph lineup and 
semen that had been found at the scene. The analyst 
identified that the semen came from a person with Type B 
blood, but Bain had Type AB blood. However, because the 
analyst said that Bain’s blood type was a weak A, he could 
not be excluded from the list of suspects. He was even-
tually convicted and sentenced to life in prison based on 
shoddy forensic science. Bain was serving his life sentence 
when Florida passed a statute in 2001 that allowed for 
cases to be reopened for DNA testing.1 After five failed 
petitions to the courts to reopen his case, he eventually 
got the help of the Innocence Project, an organization that 
seeks to exonerate wrongly convicted inmates using new 
DNA testing. According to the Innocence Project, “364 
people in the United States have been exonerated testing, 
including 20 who served time on death row.”2 The DNA 
evidence eventually exonerated Bain, who was released in 
2009— 35 years after his conviction— and was awarded 
$1.7 million by Florida. Bain’s story is one of many wrong-
ful convictions that have been overturned by new DNA 
sequencing technology.
 In criminal cases where the perpetrator is un-
known, detectives look for articles that may contain the 
perpetrator’s DNA including hair, saliva, semen, sweat, 
blood, or even skin cells. The cells are lysed, the DNA is 
isolated, then amplified and multiplied using polymerase 
chain reaction (PCR). The DNA sequence can then be 
used in short tandem repeat (STR) analysis. An individual 
has 3-7 base pair repeats, called loci, distributed through-
out their DNA. The type and number of loci repeats are 
unique in each person. In STR analysis, these loci are 
amplified and sequenced.3 Variability in a person’s STRs is 
enough to differentiate between individuals, which allows 
for DNA sequences to be compared between suspects 
for criminal investigations. In 1994, the FBI established 
the Combined DNA Index System (CODIS), a national 
DNA database that allows for DNA comparison to known 
criminals. However, this is not the only DNA database 
that law enforcement uses. Third-party DNA sequencing 
companies that analyze customers’ DNA sequences to 
determine ethnicity or family lineage including 23andMe, 
AncestryDNA, and LivingDNA have been known to share 
data with police in investigations. According to 23andMe’s 
website, they “do not share customer data with any public 
databases” but “may be required by law to comply with a 
valid court order, subpoena, or search warrant for genetic 
or personal information.”4 These “voluntary” databases 
have been used before in investigations. A 1993 murder 
case was reopened in 2015 due to the new advances in 
DNA testing and these private companies. Investigators 
sent samples from the original crime scene to a private 
DNA sequencing company and ran them through an 
online genealogy website. The test connected the DNA to 
Jerry Westrom. Using social media, the detectives fol-
lowed Westrom, eventually recovering a napkin that he 
threw out while eating a hot dog at his daughter’s hockey 
game. The DNA on the napkin was found to match the 
blood found at the crime scene, and in February, Westrom 
was charged with second-degree murder.5 Although these 
companies may be a powerful tool for investigators, their 
practices call into question an individual’s right to privacy 
with regards to their DNA, whether given voluntarily or 
not.
 DNA testing has also made its way to the Su-
preme Court. In Maryland v. King (2013), the Supreme 
Court ruled that DNA swabbing can be considered part of 
the regular arrest booking procedure alongside mug shots 
and fingerprints. Thus, when a police officer swabs the in-
side of an arrestee’s mouth to collect DNA without cause, 
the officer is not in violation of the Fourth Amendment, 
which protects against “unreasonable searches and sei-
zures” of “persons, houses, papers, and effects.” King was 
arrested for attempted violence, burglary, and attempted 
burglary. When he was booked, his DNA was run through 
CODIS and matched DNA from an unsolved rape. King 
was convicted of first-degree rape and sentenced to life 
in prison. King appealed his case, arguing that the cheek 
swab was an unconstitutional search in violation of his 
Fourth Amendment rights against warrantless searches. 
The Court ruled against King saying the search was not a 
violation. Justice Kennedy, writing for the majority, said 
that a cheek swab “involves but a light touch on the inside 
of the cheek . . . The fact that an intrusion is negligible 
is of central relevance to determining reasonableness, 
although it is still a search as the law defines that term.”6 
Essentially, because the swab is unobtrusive, it is not 
unreasonable for a police officer to undergo a “search” 
without cause. This allows for police officers to utilize the 
wide capabilities of DNA testing to solve crimes without 
needing to obtain a warrant. Although this would bring a 
host of good in crime solving, it could be readily abused, 
which the Fourth Amendment is meant to protect against. 
Justice Scalia, writing a dissenting opinion in which 
Justices Sotomayor, Ginsburg, and Kagan joined, categor-
ically prevents officers from performing a search without 
cause. The Court has always held that “no matter the 
degree of invasiveness, suspicionless searches are never 
allowed if their principal end is ordinary crime-solving.” 
Scalia continues saying that the Court’s ruling “will, to 
be sure, have the beneficial effect of solving more crimes; 
then again, so would the taking of DNA samples from 
anyone who flies on an airplane, applies for a driver’s 
license, or attends a public school.” The increasing capa-
bilities of DNA testing should be carefully regulated just 
as with any new technology that can have implications on 
the legal system. As powerful as these new technologies 
are for exoneration and crime solving, individuals’ privacy 
should be given proper weight and protections in the face 
of the extraordinary capabilities of DNA testing.
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t’s that time of the season again, as the sniffs and 
coughs begin to rapidly spread throughout campus. 
Despite how hard you try to avoid all who are infected, 
no doubt you will wake up soon enough with a tickle in 
your throat and a waterfall running from your nose. As a 
college student, you can’t go all the way back home to your 
family physician, and the university’s clinic is booked for 
days. So, you drive to the nearest Walgreens and walk into 
the MinuteClinic. Here, within an hour you’re able to check 
in, get evaluated and diagnosed by a healthcare professional, 
and walk out the door with a prescription in one hand and a 
copy of your medical results in the other. 
History
 The MinuteClinic is one of the many branches of 
retail clinics growing across the US as an alternative for 
primary care treatment. First opened in 2001, retail clinics 
began with a Rick Krieger’s frustrations when he was put on 
a long standby, waiting for his son’s diagnosis and treatment. 
Because of this frustration, Krieger became the cofounder 
of the first MinuteClinic. It wasn’t until 2006 that these 
retail clinics would rapidly expand with CVS Caremark 
Corporation buying the rights to the MinuteClinic. This led 
to the establishment of over 1,000 clinics within the next 
five years. Now in 2019, there are over 2,800 retail clinics 
throughout the US available for screening and diagnosing 
patients (Burkle, 2011). 
Why the rise in retail clinics?
 Retail clinics have developed from the one value 
that our culture holds highest: convenience. For retail clinics, 
the convenience of widely-accepted insurance, low costs, 
and flexibility in location and times acts as a catalyst to their 
rapid expansion and takeover of the primary care market. 
Before visiting any provider, insurance is the first concern 
for any patient. The 2010 Affordable Care Act resulted in 
an increased number of individuals able to gain insurance. 
As a result, retail clinics thrive on their ability to accept 
these, and many more different types of insurance, despite 
what reimbursement they may receive. This includes private 
insurances from employers to public ones such as Medicare 
and Medicaid, which reimburse at lower rates than private. 
Even after insurance, co-pays can still be an expensive chunk 
out of any anyone’s pocket. The staff and model employed by 
retail clinics, however, have shown to cost less than that of 
other health providers. On average, a visit to any retail clinic 
costs about $110 versus a range of $150 to $570 for a visit 
to a physician, urgent care clinic, or the emergency room 
(ER) (Mehotra et. al, 2009). These low costs, in comparison 
to other medical providers, are a high incentive for patients 
who aren’t able to afford the high costs of healthcare or 
whose insurance doesn’t completely cover the costs of 
physician visits.
 Lastly, is the availability of these retail clinics— both 
in location and hours. While the number of clinics in each 
state varies, for 35 percent of Americans a retail clinic is 
no less than a 10-minute drive away (Marsolf et. al, 2016). 
The close proximity of these locations in combination with 
extended weekday and weekend hours only widen the range 
of patients able to be seen. In comparison, physician’s office 
are usually a solo location that have limited hours on the 
weekend, if any. This facets then severely limit the patients 
able to be seen in comparison to a retail clinic. 
Are retail clinics helping or hurting?
 Despite all the patients that retail clinics are 
accessible to, due to their costs and availability, it’s important 
to ask: Are patients getting the quality of care needed 
by these retail clinic providers? According to studies, it 
depends. A study done by Shrank and other researchers in 
2014 looked at over 20,000 medical cases from 2009 to 2012 
to study if a measured and objective standard quality of care 
was met by these retail clinics. Their results showed that the 
quality of care was not only competent, but in the case of 
certain acute conditions, the quality of care was better than 
other medical providers. In addressing common conditions 
such as the flu or urinary tract infections (UTIs), retail 
clinics can be excellent providers in terms of lower costs 
and availability and an uncompromised quality of care for 
patients. 
 Chronic conditions, on the other hand, are a 
different story. Nitin Damle, MD and President of the 
American College of Physicians (ACP), states, “We don’t 
think there is enough evidence to say that they are able to 
take care of chronic disease to manage complex problems.” 
Chronic diagnoses can be intricate diagnoses that often 
require a team of healthcare providers— each specialized 
to address some aspect of your diagnosis, whether it’s a 
nutritionist or a gastroenterologist. These types of teams 
can typically only be established in a physician’s office or the 
hospital. 
Future of retail clinics
 What will the role of retail clinics be in the future 
then? While retain clinics continue to outcompete other 
primary care providers in terms of convenience, patient 
safety and quality of care comes first. This has been the basis 
of rivalry between retail clinics and physicians as physicians 
strongly believe there is no role for chronic care management 
in retail clinics. While it may seem like the path ahead would 
be filled with competition between these two in addressing 
primary care shortages, another path is being paved.
Rather than attempting to outcompete each other, 
physicians’ offices and hospitals have joined in collaboration 
with retail clinics in order to bridge the gaps in patients. In 
Ohio, Walgreens’ MinuteClinics are now partnering with 
hospitals like the Cleveland Clinic. Through this partnership, 
the two can evaluate all the facets of primary care to ensure 
the delivery of what either system may lack in caring for its 
patients. With that idea in mind, it’s important to note that 
retail clinics can be an adequate, if not convenient, primary 
care provider when used properly. However, these clinics 
are not cure-alls, but rather a single facet in the healthcare 
system of delivering care. By continuing to work together 
and not against each other, the future looks bright for a more 
integrated health care delivery system using a collaboration 
between retail clinics, physician’s offices, and hospitals.
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1. When did you first learn of your interest in 
medicine? 
• I always wanted to go into medicine. There was 
no clear, inciting event that led me that way. In 
general, I enjoyed figuring things out and putting 
the pieces together to solve problems. I was 
always drawn to the human element of working 
with people and helping them through difficult 
situations. These were the main reasons that I 
pursued medicine.
2. How did you know it was right for you? 
Did you know?
• I knew I had the right skill set for medicine. I 
liked directly helping people. I considered other 
things, such as law, but none of them appealed 
to me in the same fashion.
3. Where did you go to undergrad, and what 
did you major in?
• I attended UVA and majored in Biology and 
American Politics. 
4. Where did you go to medical school and 
why? 
• I went to Eastern Virginia Medical School 
(EVMS). I chose it because it was close to 
home without being too close. I wanted to stay 
in Virginia. I liked that it had a smaller class size 
than VCU and I liked that I wouldn’t get farmed 
out to other locations like UVA does.
5. What other passions do you have that are 
either in medicine or outside of medicine?
• I’m very interested in sports and music. I 
was head assistant of the basketball team at 
my old high school before my son was born. 
Additionally, I am learning to play the piano right 
now. 
6. What is your specialty? 
• Cardiology. 
7. Where did you do your residency? 
• I did my residency and fellowship at VCU. 
8. Years in Practice?
• I am finishing up my third year. 
9. What is your practice setting/employment 
Type?
• I work in a community setting for a private group. 
I am currently on a partnership track. 
10. What kinds of other practice settings 
exist?
• Many practice types exist; other cardiologists 
are employed by a hospital corporation or by an 
academic institution. 
11. What does your specialty entail?
• Cardiology involves both inpatient and outpatient 
care. I perform cardiac catheterizations and 
implant temporary internal pacemakers 
and internal monitoring devices to measure 
intracardiac pressure and arrhythmias. 
Additionally, I interpret transesophageal 
echocardiograms, Holter monitors, nuclear 
stress tests, and PET stress tests. Other 
types of cardiologists include interventional 
cardiologists and electrophysiologists. 
Interventional cardiologists put in stents, artificial 
valves, occluder devices, and valve clips. 
Electrophysiologists’ duties include pacemaker 
and defibrillator implantation and ablations. 
Ablations are procedures to make an electrical 
map of the heart and then destroy abnormal 
electrical tissue which leads to irregular heart 
rhythms. This can be done by using cryoablation 
(cold), radiofrequency ablation (heat), or lasers. 
12. What does a typical day look like for 
you? If you can call it typical. 
• A typical day involves a half day of clinic where I 
see 10-12 patients, on average. The other half of 
the day involves treating hospital patients. This 
is when I do procedures or interpret studies, as 
well as make phone calls to my patients.
13. What was the path to your specialty? 
(medicine-residency-fellowship?)
• I graduated in 2002 from UVA. From there, I 
worked for one year as an emergency room 
scribe. I continued working from 2003-2005 
while I earned a master’s degree in physiology 
from VCU. I went to EVMS from 2005-2009. 
Next, I did an internal medicine residency at 
VCU from 2009-2012. I worked one year as 
a hospitalist (inpatient medicine) at VCU from 
2012-2013. Finally, I did my fellowship at VCU 
from 2013-2016
14. What is your favorite part about 
Cardiovascular or about medicine in 
general?
• Cardiology is an extremely flexible and growing 
field. Tasks, which were previously surgical in 
nature, can now be done using catheters. It is 
flexible in that you can be procedurally oriented 
or never do procedures. I like to say that you 
can customize your practice to whatever you 
enjoy. You can wear scrubs all day and perform 
procedures, or you can work in a clinical 
setting and never see a drop of blood. The 
field is also very cutting edge and guideline 
driven with strong research predicating our 
recommendations. It is very satisfying to directly 
impact patients’ lives.  
15. What is your least favorite part about 
your job?
• As a cardiologist, many other fields defer to 
you as the final gatekeeper for a procedure 
or decision. “If it’s OK with cardiology” or, 
“cardiology has cleared them” are things that 
are said and written all the time. If bad things 
happen, it can be frustrating for people to look 
at you when you really had nothing to do with 
the outcome or situation. It is, however, neat to 
be held in that regard, but it adds pressure and 
anxiety to the job. 
16. What was your most challenging/difficult 
case and why?
• In general, arterial procedures can be quite 
difficult. You can follow the procedures and do 
everything right, but you may still end up with 
some bad outcomes. There are safe guards in 
place to ensure that all of the instruments are 
working properly, but, the “swiss cheese theory” 
can still apply. There can be procedures where 
“the holes” in all the bits of cheese line up. In 
this analogy, it means that sometimes, things 
can happen that are out of your control. The 
hardest part is going into the next procedure with 
another patient and maintaining your confidence. 
Confidence is vital for working in a procedural 
field. 
17. Do you have a time that you experienced 
failure or struggle in med school or 
residency, and how did you overcome it?
• Everyone fails and struggles at some point. 
Long hours and lots of stress can be difficult to 
manage. Often times, family and friends don’t 
understand what you are going through. Many 
decisions are made, and some are wrong. You 
overcome it by being honest with yourself and 
honest with your colleagues. Don’t be afraid to 
ask for help; take advice from people who care. 
18. What specialty(s) did you originally 
think you were going to end up in when you 
entered medical school? What changed?
• I thought I would end up in either a subspecialty 
of medicine or surgery. I wasn’t sure which one. 
I wanted something with flexibility where I could 
do many different things, as it keeps work from 
getting mundane. 
19. What was your favorite part about 
medical school/residency?
• The friends that I made through all of the steps 
was the best part. It makes working hard more 
tolerable and allows for you to lean on others 
and become stronger.
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20. What is one skill that you have that you 
feel has helped you achieve all that you 
have?
• I think that I am pretty empathic. When you are 
able to put yourself in another’s shoes and try 
to better understand and appreciate another 
person’s situation, it makes you and your 
recommendations more effective because it 
allows you to be both a better listener and more 
persuasive.
21. What personality do you think are 
required or necessary in Cardiovascular?
• No specific personality is needed because there 
are so many different types of cardiologists.
22. What is one piece of advice you would 
give to those pursuing medicine today?
• Becoming a physician is a marathon. Don’t 
get too high when things are going well and 
don’t get too low when you have a setback. 
Everyone will have highs and lows; it’s just part 
of the game. I recommend pursuing interests 
outside of medicine. It gives you something to 
look forward to and gets your mind off of work/
studying.
23. What are the fields/aspects in medicine 
you feel are on rise? What fields or aspects 
are on the decline?
• Rise – more research-based guidelines with 
strong scientific background are on the rise. 
Recommendations are now, more than ever, 
founded in research.  Cardiology is one of 
the fields that has the most scientific studies 
and clinical trials. I can point to specific trials 
to inform my patient why I am recommending 
certain treatments. Technology advancements 
are on the rise too. We have access to new tools 
that make procedures less invasive.
• Decline – autonomy. Many jobs now involve 
being employed by others such as a hospital 
system or a university. I know of physicians who 
are less aggressive with patients as they fear 
bad outcomes to which they have to answer to 
someone who has little health care experience 
and is only looking at the bottom line.
24. How has medicine affected your home 
life? Do you feel that you have missed out 
on any aspect of life because of medicine? 
Is it possible to have a full life in your field? 
• Medical training dominates your 20s. There 
will be times where you won’t be able to do 
something you want to do because of work/tests/
call/whatever. Some relationships (romantic 
or non-romantic) may suffer because of your 
stress/hours. There are things that you will 
miss out on. However, it is definitely possible to 
have a full life and have interests and pastimes 
outside of medicine. One just needs to be 
prepared that priorities need to be sound and 
not get completely wrapped up in medicine. 
You can’t do your best job if you are miserable 
because you will burn out, cut corners, and not 
be as diligent as you should.
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